Last reviewed · How we verify

Tezspire — Competitive Intelligence Brief

Tezspire (TEZEPELUMAB) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thymic Stromal Lymphopoietin Blocker [EPC].

marketed Thymic Stromal Lymphopoietin Blocker [EPC] Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Tezspire (TEZEPELUMAB) — AstraZeneca / Amgen.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tezspire TARGET TEZEPELUMAB AstraZeneca / Amgen marketed Thymic Stromal Lymphopoietin Blocker [EPC] 2021-01-01
Tezspire AMG 157 AstraZeneca marketed Thymic Stromal Lymphopoietin Blocker [EPC] Thymic stromal lymphopoietin 2021-01-01
TEZSPIRE TEZEPELUMAB-EKKO ASTRAZENECA AB marketed Thymic Stromal Lymphopoietin Blocker [EPC] Thymic stromal lymphopoietin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thymic Stromal Lymphopoietin Blocker [EPC] class)

  1. ASTRAZENECA AB · 1 drug in this class
  2. AstraZeneca · 1 drug in this class
  3. AstraZeneca / Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tezspire — Competitive Intelligence Brief. https://druglandscape.com/ci/tezepelumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: